Furthermore, another study by Krause et al. demonstrated that liraglutide is a potent candidate for the treatment of HCC, as it had an antiproliferative effect in HepG2 cells inducing autophagy and senescence by the increase of TGF-β1, without altering oxidative stress levels, via the inhibition of the PI3K/Akt/mTOR pathway in HCC [62]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.